1
|
Wu R, Chen H, Chang N, Xu Y, Jiao J, Zhang H. Unlocking the Drug Potential of the Bryostatin Family: Recent Advances in Product Synthesis and Biomedical Applications. Chemistry 2019; 26:1166-1195. [PMID: 31479550 DOI: 10.1002/chem.201903128] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2019] [Revised: 09/01/2019] [Indexed: 12/14/2022]
Abstract
Bryostatins are a class of naturally occurring macrocyclic lactones with a unique fast developing portfolio of clinical applications, including treatment of AIDS, Alzheimer's disease, and cancer. This comprehensive account summarizes the recent progress (2014-present) in the development of bryostatins, including their total synthesis and biomedical applications. An emphasis is placed on the discussion of bryostatin 1, the most-studied analogue to date. This review highlights the synthetic and biological challenges of bryostatins and provides an outlook on their future development.
Collapse
Affiliation(s)
- Rongzhen Wu
- Department of Chemistry, Southern University of Science and Technology of China, Shenzhen, 518055, P. R. China
| | - Hongyu Chen
- Department of Biology, Southern University of Science and Technology of China, Shenzhen, 518055, P. R. China
| | - Ninghui Chang
- Department of Chemistry, School of Science, Northwestern Polytechnical University, Xi'an, 710072, P. R. China
| | - Yuzhi Xu
- School of Materials Science and Engineering, South China University of Technology, Guangzhou, 510006, P. R. China
| | - Jiao Jiao
- Department of Chemistry, School of Science, Xi'an Key Laboratory of Sustainable Energy Materials Chemistry, Xi'an Jiaotong University, Xi'an, 710049, P. R. China
| | - Hailong Zhang
- School of Pharmacy, Xi'an Jiaotong University, Xi'an, 710061, P. R. China
| |
Collapse
|
2
|
Itoh H, Inoue M. Comprehensive Structure–Activity Relationship Studies of Macrocyclic Natural Products Enabled by Their Total Syntheses. Chem Rev 2019; 119:10002-10031. [DOI: 10.1021/acs.chemrev.9b00063] [Citation(s) in RCA: 52] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
- Hiroaki Itoh
- Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
| | - Masayuki Inoue
- Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
| |
Collapse
|
3
|
Cummins TJ, Kedei N, Czikora A, Lewin NE, Kirk S, Petersen ME, McGowan KM, Chen JQ, Luo X, Johnson RC, Ravichandran S, Blumberg PM, Keck GE. Synthesis and Biological Evaluation of Fluorescent Bryostatin Analogues. Chembiochem 2018; 19:877-889. [PMID: 29424951 DOI: 10.1002/cbic.201700655] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2017] [Indexed: 11/10/2022]
Abstract
To investigate the cellular distribution of tumor-promoting vs. non-tumor-promoting bryostatin analogues, we synthesized fluorescently labeled variants of two bryostatin derivatives that have previously shown either phorbol ester-like or bryostatin-like biological activity in U937 leukemia cells. These new fluorescent analogues both displayed high affinity for protein kinase C (PKC) binding and retained the basic properties of the parent unlabeled compounds in U937 assays. The fluorescent compounds showed similar patterns of intracellular distribution in cells, however; this argues against an existing hypothesis that various patterns of intracellular distribution are responsible for differences in biological activity. Upon further characterization, the fluorescent compounds revealed a slow rate of cellular uptake; correspondingly, they showed reduced activity for cellular responses that were only transient upon treatment with phorbol ester or bryostatin 1.
Collapse
Affiliation(s)
- Thomas J Cummins
- University of Utah, Department of Chemistry, 315 South 1400 East, Room 2020, Salt Lake City, UT, 84112, USA
| | - Noemi Kedei
- Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, 37 Convent Drive, Room 4048, Bethesda, MD, 20892, USA
| | - Agnes Czikora
- Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, 37 Convent Drive, Room 4048, Bethesda, MD, 20892, USA
| | - Nancy E Lewin
- Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, 37 Convent Drive, Room 4048, Bethesda, MD, 20892, USA
| | - Sharon Kirk
- University of Utah, Department of Chemistry, 315 South 1400 East, Room 2020, Salt Lake City, UT, 84112, USA
| | - Mark E Petersen
- University of Utah, Department of Chemistry, 315 South 1400 East, Room 2020, Salt Lake City, UT, 84112, USA
| | - Kevin M McGowan
- University of Utah, Department of Chemistry, 315 South 1400 East, Room 2020, Salt Lake City, UT, 84112, USA
| | - Jin-Qiu Chen
- Collaborative Protein Technology Resource, Center for Cancer Research, National Cancer Institute, 37 Convent Drive, Room 1044, Bethesda, MD, 20892, USA
| | - Xiaoling Luo
- Collaborative Protein Technology Resource, Center for Cancer Research, National Cancer Institute, 37 Convent Drive, Room 1044, Bethesda, MD, 20892, USA
| | - Randall C Johnson
- Advanced Biomedical and Computational Sciences Biomedical Informatics, and Data Science (BIDS), Directorate Frederick National Laboratory for Cancer Research (FNLCR), Leidos Biomedical Research, Inc., Building 430, Miller Drive, Fort Detrick, Frederick, MD, 21702, USA
| | - Sarangan Ravichandran
- Advanced Biomedical and Computational Sciences Biomedical Informatics, and Data Science (BIDS), Directorate Frederick National Laboratory for Cancer Research (FNLCR), Leidos Biomedical Research, Inc., Building 430, Miller Drive, Fort Detrick, Frederick, MD, 21702, USA
| | - Peter M Blumberg
- Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, 37 Convent Drive, Room 4048, Bethesda, MD, 20892, USA
| | - Gary E Keck
- University of Utah, Department of Chemistry, 315 South 1400 East, Room 2020, Salt Lake City, UT, 84112, USA
| |
Collapse
|
4
|
Crane EA, Gademann K. Synthetisch gewonnene Naturstofffragmente in der Wirkstoffentwicklung. Angew Chem Int Ed Engl 2016. [DOI: 10.1002/ange.201505863] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Affiliation(s)
- Erika A. Crane
- Departement Chemie; Universität Basel; St. Johanns-Ring 19 CH-4056 Basel Schweiz
| | - Karl Gademann
- Departement Chemie; Universität Basel; St. Johanns-Ring 19 CH-4056 Basel Schweiz
- Institut für Chemie; Universität Zürich; Winterthurerstrasse 190 CH-8057 Zürich Schweiz
| |
Collapse
|
5
|
Crane EA, Gademann K. Capturing Biological Activity in Natural Product Fragments by Chemical Synthesis. Angew Chem Int Ed Engl 2016; 55:3882-902. [PMID: 26833854 PMCID: PMC4797711 DOI: 10.1002/anie.201505863] [Citation(s) in RCA: 106] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2015] [Indexed: 12/22/2022]
Abstract
Natural products have had an immense influence on science and have directly led to the introduction of many drugs. Organic chemistry, and its unique ability to tailor natural products through synthesis, provides an extraordinary approach to unlock the full potential of natural products. In this Review, an approach based on natural product derived fragments is presented that can successfully address some of the current challenges in drug discovery. These fragments often display significantly reduced molecular weights, reduced structural complexity, a reduced number of synthetic steps, while retaining or even improving key biological parameters such as potency or selectivity. Examples from various stages of the drug development process up to the clinic are presented. In addition, this process can be leveraged by recent developments such as genome mining, antibody–drug conjugates, and computational approaches. All these concepts have the potential to identify the next generation of drug candidates inspired by natural products.
Collapse
Affiliation(s)
- Erika A Crane
- Department of Chemistry, University of Basel, Switzerland
| | - Karl Gademann
- Department of Chemistry, University of Basel, Switzerland. .,Department of Chemistry, University of Zürich, Winterthurerstrasse 190, CH-8057, Zürich, Switzerland.
| |
Collapse
|
6
|
Kraft M, Poudel YB, Kedei N, Lewin N, Peach ML, Blumberg PM, Keck GE. Synthesis of a des-B-ring bryostatin analogue leads to an unexpected ring expansion of the bryolactone core. J Am Chem Soc 2014; 136:13202-8. [PMID: 25207434 PMCID: PMC4183620 DOI: 10.1021/ja5078188] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2014] [Indexed: 11/28/2022]
Abstract
A convergent synthesis of a des-B-ring bryostatin analogue is described. This analogue was found to undergo an unexpected ring expansion of the bryolactone core to generate the corresponding 21-membered macrocycle. The parent analogue and the ring-expanded product both displayed nanomolar binding affinity for PKC. Despite containing A-ring substitution identical to that of bryostatin 1 and displaying bryostatin-like biological function, the des-B-ring analogues displayed a phorbol-like biological function in cells. These studies shed new light on the role of the bryostatin B-ring in conferring bryo-like biological function to bryostatin analogues.
Collapse
Affiliation(s)
- Matthew
B. Kraft
- Department
of Chemistry, University of Utah, Salt Lake City, Utah 84112, United States
| | - Yam B. Poudel
- Department
of Chemistry, University of Utah, Salt Lake City, Utah 84112, United States
| | - Noemi Kedei
- Laboratory
of Cancer Biology and Genetics, National
Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-4255, United States
| | - Nancy
E. Lewin
- Laboratory
of Cancer Biology and Genetics, National
Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-4255, United States
| | - Megan L. Peach
- Basic Science Program,
Leidos Biomedical Research, Inc., Chemical Biology Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702, United States
| | - Peter M. Blumberg
- Laboratory
of Cancer Biology and Genetics, National
Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-4255, United States
| | - Gary E. Keck
- Department
of Chemistry, University of Utah, Salt Lake City, Utah 84112, United States
| |
Collapse
|
7
|
Wender PA, Donnelly AC, Loy BA, Near KE, Staveness D. Rethinking the Role of Natural Products: Function-Oriented Synthesis, Bryostatin, and Bryologs. METHODS AND PRINCIPLES IN MEDICINAL CHEMISTRY 2014. [DOI: 10.1002/9783527676545.ch14] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/03/2022]
|
8
|
Wender PA, Reuber J. Function Oriented Synthesis: Preparation and Initial Biological Evaluation of New A-Ring-Modified Bryologs. Tetrahedron 2011; 67:9998-10005. [PMID: 22247574 DOI: 10.1016/j.tet.2011.09.058] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The synthesis and biological evaluation of the first members of a new series of designed bryostatin A-ring analogues (bryologs) are described. An advanced intermediate is produced that allows for step economical access to diverse analogs. The first of these analogues, bearing side chains of completely different polarities from alkyl to hydroxyl and carboxyl functionalities, were evaluated. All exhibit potent protein kinase C binding (54.7 to 2.4 nM) with affinities increasing with decreasing side chain polarity. This series of bryostatin analogues demonstrates that A ring surrogates can indeed be used for tuning pharmacophore and ADME characteristics as needed to improve bryolog function.
Collapse
Affiliation(s)
- Paul A Wender
- Department of Chemistry, Department of Chemical and Systems Biology, Stanford University, Stanford, California 94305-5080, USA
| | | |
Collapse
|
9
|
Wender PA, Loy BA, Schrier AJ. Translating Nature's Library: The Bryostatins and Function-Oriented Synthesis. Isr J Chem 2011; 51:453-472. [PMID: 22661768 PMCID: PMC3364006 DOI: 10.1002/ijch.201100020] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
We review in part our computational, design, synthesis, and biological studies on a remarkable class of compounds and their designed analogs that have led to preclinical candidates for the treatment of cancer, a first-in-class approach to Alzheimer's disease, and a promising strategy to eradicate HIV/AIDS. Because these leads target, in part, protein kinase C (PKC) isozymes, they have therapeutic potential even beyond this striking set of therapeutic indications. This program has given rise to new synthetic methodology and represents an increasingly important direction of synthesis focused on achieving function through synthesis-informed design (function-oriented synthesis).
Collapse
Affiliation(s)
- Paul A. Wender
- Department of Chemistry Department of Chemical and Systems Biology Stanford University Stanford, CA 94305, USA
| | - Brian A. Loy
- Department of Chemistry Department of Chemical and Systems Biology Stanford University Stanford, CA 94305, USA
| | - Adam J. Schrier
- Department of Chemistry Department of Chemical and Systems Biology Stanford University Stanford, CA 94305, USA
| |
Collapse
|
10
|
Szpilman AM, Carreira EM. Probing the Biology of Natural Products: Molecular Editing by Diverted Total Synthesis. Angew Chem Int Ed Engl 2010; 49:9592-628. [DOI: 10.1002/anie.200904761] [Citation(s) in RCA: 150] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
11
|
Szpilman AM, Carreira EM. Untersuchung der Biologie von Naturstoffen: systematische Strukturvariation durch umgelenkte Totalsynthese. Angew Chem Int Ed Engl 2010. [DOI: 10.1002/ange.200904761] [Citation(s) in RCA: 60] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
|
12
|
Beutler JA. Natural Products as a Foundation for Drug Discovery. CURRENT PROTOCOLS IN PHARMACOLOGY 2009; 46:9.11.1-9.11.21. [PMID: 20161632 PMCID: PMC2813068 DOI: 10.1002/0471141755.ph0911s46] [Citation(s) in RCA: 122] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
Natural products have contributed to the development of many drugs for diverse indications. While most U.S. pharmaceutical companies have reduced or eliminated their in-house natural product groups, new paradigms and new enterprises have evolved to carry on a role for natural products in the pharmaceutical industry. Many of the reasons for the decline in popularity of natural products are being addressed by the development of new techniques for screening and production. This overview aims to inform pharmacologists of current strategies and techniques that make natural products a viable strategic choice for inclusion in drug discovery programs.
Collapse
Affiliation(s)
- John A Beutler
- Molecular Targets Development Program Center for Cancer Research National Cancer Institute Frederick, MD 21702 USA 301-846-1942 (ph.) 301-846-6177 (fax)
| |
Collapse
|
13
|
Ku GY, Ilson DH, Schwartz LH, Capanu M, O'Reilly E, Shah MA, Kelsen DP, Schwartz GK. Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer. Cancer Chemother Pharmacol 2008; 62:875-80. [PMID: 18270704 DOI: 10.1007/s00280-008-0677-y] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2007] [Accepted: 01/06/2008] [Indexed: 12/11/2022]
Abstract
BACKGROUND We sought to determine the response rate and toxicity profile of sequential paclitaxel and bryostatin-1, a novel, selective inhibitor of protein kinase C, in patients with advanced esophageal cancer. PATIENTS AND METHODS Patients with advanced esophageal and gastroesophageal junction cancer were enrolled. All gave informed consent. They were initially treated with paclitaxel 90 mg/m(2) intravenously on Day 1 and bryostatin-1 50 microg/m2 on Day 2 weekly for three consecutive weeks out of four. Because of severe myalgias, dosing was reduced to paclitaxel 80 mg/m2 with bryostatin-1 40 microg/m2 and then to paclitaxel 80 mg/m2 with bryostatin-1 25 microg/m2. RESULTS Twenty-four patients were enrolled, with 22 assessable for response. The partial response rate was 27%. 10 patients treated with bryostatin-1 40-50 microg/m2 had a response rate of 40 versus 17% at bryostatin-1 25 microg/m2 (p-value = 0.3). Median time-to-progression was 3.7 months and median survival was 8.3 months. Grade 3/4 myalgias were seen in 50% of patients. Myalgias appeared to be related to bryostatin-1 dose. Because of toxicity, the trial was closed prior to full accrual. CONCLUSIONS Despite potential anti-tumor activity of this combination in patients with advanced esophageal cancer, further development is not warranted, given the severe toxicity, especially myalgias, that were seen.
Collapse
Affiliation(s)
- Geoffrey Y Ku
- Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
| | | | | | | | | | | | | | | |
Collapse
|
14
|
|
15
|
Herndon JW. The chemistry of the carbon–transition metal double and triple bond: Annual survey covering the year 2005. Coord Chem Rev 2007. [DOI: 10.1016/j.ccr.2006.11.002] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
16
|
Abstract
Bryostatin-1 is a powerful protein kinase C (PKC) agonist, activating PKC isozymes at nanomolar concentrations. Pharmacological studies of bryostatin-1 have mainly been focused on its action in preventing tumor growth. Emerging evidence suggests, however, that bryostatin-1 exhibits additional important pharmacological activities. In preclinical studies bryostatin-1 has been shown at appropriate doses to have cognitive restorative and antidepressant effects. The underlying pharmacological mechanisms may involve an activation of PKC isozymes, induction of synthesis of proteins required for long-term memory, restoration of stress-evoked inhibition of PKC activity, and reduction of neurotoxic amyloid accumulation and tau protein hyperphosphorylation. The therapeutic potential of bryostatin-1 as a CNS drug should be further explored.
Collapse
Affiliation(s)
- Miao-Kun Sun
- Blanchette Rockefeller Neurosciences Institute, Rockville, MD 20850, USA.
| | | |
Collapse
|
17
|
Manaviazar S, Frigerio M, Bhatia GS, Hummersone MG, Aliev AE, Hale KJ. Enantioselective Formal Total Synthesis of the Antitumor Macrolide Bryostatin 7. Org Lett 2006; 8:4477-80. [PMID: 16986929 DOI: 10.1021/ol061626i] [Citation(s) in RCA: 77] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
A new enantioselective synthesis of Masamune's AB fragment (1) for bryostatin 7 is described. Key steps in the new route include a Meerwein-Ponndorf-Verley reduction to set the O(7) stereocenter and an alkylative union between the dithiane 6 and iodide 5 to construct the C(9)-C(10) bond. Because we have previously published a synthesis of Masamune's C-ring phenyl sulfone 2, our new route to 1 constitutes a formal total synthesis of bryostatin 7; it also corrects the previously reported spectral data for 1 in CDCl3.
Collapse
Affiliation(s)
- Soraya Manaviazar
- UCL Center for Chemical Genomics, Christopher Ingold Laboratories, Chemistry Department, University College London, 20 Gordon Street, London WC1H 0AJ, UK.
| | | | | | | | | | | |
Collapse
|
18
|
Wender PA, Horan JC. Synthesis and PKC Binding of a New Class of A-Ring Diversifiable Bryostatin Analogues Utilizing a Double Asymmetric Hydrogenation and Cross-Coupling Strategy. Org Lett 2006; 8:4581-4. [PMID: 16986955 DOI: 10.1021/ol0618149] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The design, asymmetric synthesis, and biological evaluation of a new class of bryostatin analogues based on a pseudosymmetric spacer domain are described. An aryl bromide diversification site is incorporated allowing access to systematically varied analogues. The new analogues all exhibit potent, nanomolar affinity to PKC.
Collapse
Affiliation(s)
- Paul A Wender
- Department of Chemistry, Stanford University, Stanford, California 94305-5080, USA.
| | | |
Collapse
|